TY - JOUR
T1 - Adrenaline Stimulates Glucagon Secretion by Tpc2-Dependent Ca2+ Mobilization From Acidic Stores in Pancreatic α-Cells
AU - Hamilton, Alexander
AU - Zhang, Quan
AU - Salehi, Albert
AU - Willems, Mara
AU - Knudsen, Jakob G
AU - Ringgaard, Anna K
AU - Chapman, Caroline E
AU - Gonzalez-Alvarez, Alejandro
AU - Surdo, Nicoletta C
AU - Zaccolo, Manuela
AU - Basco, Davide
AU - Johnson, Paul R V
AU - Ramracheya, Reshma
AU - Rutter, Guy A
AU - Galione, Antony
AU - Rorsman, Patrik
AU - Tarasov, Andrei I
N1 - © 2018 by the American Diabetes Association.
PY - 2018/6
Y1 - 2018/6
N2 - Adrenaline is a powerful stimulus of glucagon secretion. It acts by activation of β-adrenergic receptors, but the downstream mechanisms have only been partially elucidated. Here, we have examined the effects of adrenaline in mouse and human α-cells by a combination of electrophysiology, imaging of Ca2+ and PKA activity, and hormone release measurements. We found that stimulation of glucagon secretion correlated with a PKA- and EPAC2-dependent (inhibited by PKI and ESI-05, respectively) elevation of [Ca2+]i in α-cells, which occurred without stimulation of electrical activity and persisted in the absence of extracellular Ca2+ but was sensitive to ryanodine, bafilomycin, and thapsigargin. Adrenaline also increased [Ca2+]i in α-cells in human islets. Genetic or pharmacological inhibition of the Tpc2 channel (that mediates Ca2+ release from acidic intracellular stores) abolished the stimulatory effect of adrenaline on glucagon secretion and reduced the elevation of [Ca2+]i Furthermore, in Tpc2-deficient islets, ryanodine exerted no additive inhibitory effect. These data suggest that β-adrenergic stimulation of glucagon secretion is controlled by a hierarchy of [Ca2+]i signaling in the α-cell that is initiated by cAMP-induced Tpc2-dependent Ca2+ release from the acidic stores and further amplified by Ca2+-induced Ca2+ release from the sarco/endoplasmic reticulum.
AB - Adrenaline is a powerful stimulus of glucagon secretion. It acts by activation of β-adrenergic receptors, but the downstream mechanisms have only been partially elucidated. Here, we have examined the effects of adrenaline in mouse and human α-cells by a combination of electrophysiology, imaging of Ca2+ and PKA activity, and hormone release measurements. We found that stimulation of glucagon secretion correlated with a PKA- and EPAC2-dependent (inhibited by PKI and ESI-05, respectively) elevation of [Ca2+]i in α-cells, which occurred without stimulation of electrical activity and persisted in the absence of extracellular Ca2+ but was sensitive to ryanodine, bafilomycin, and thapsigargin. Adrenaline also increased [Ca2+]i in α-cells in human islets. Genetic or pharmacological inhibition of the Tpc2 channel (that mediates Ca2+ release from acidic intracellular stores) abolished the stimulatory effect of adrenaline on glucagon secretion and reduced the elevation of [Ca2+]i Furthermore, in Tpc2-deficient islets, ryanodine exerted no additive inhibitory effect. These data suggest that β-adrenergic stimulation of glucagon secretion is controlled by a hierarchy of [Ca2+]i signaling in the α-cell that is initiated by cAMP-induced Tpc2-dependent Ca2+ release from the acidic stores and further amplified by Ca2+-induced Ca2+ release from the sarco/endoplasmic reticulum.
KW - Adrenergic Neurons/cytology
KW - Animals
KW - Animals, Outbred Strains
KW - Calcium Channels/chemistry
KW - Calcium Signaling/drug effects
KW - Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors
KW - Endoplasmic Reticulum/drug effects
KW - Enzyme Inhibitors/pharmacology
KW - Epinephrine/metabolism
KW - Glucagon/metabolism
KW - Glucagon-Secreting Cells/cytology
KW - Guanine Nucleotide Exchange Factors/antagonists & inhibitors
KW - Humans
KW - Membrane Transport Modulators/pharmacology
KW - Mice
KW - Mice, Inbred C57BL
KW - Mice, Knockout
KW - Pancreas/drug effects
KW - Patch-Clamp Techniques
KW - Sarcoplasmic Reticulum/drug effects
KW - Tissue Culture Techniques
KW - Up-Regulation/drug effects
U2 - 10.2337/db17-1102
DO - 10.2337/db17-1102
M3 - Article
C2 - 29563152
VL - 67
SP - 1128
EP - 1139
JO - Diabetes
JF - Diabetes
SN - 1939-327X
IS - 6
ER -